Calcitonin | Jotup

Teva Announces Ministry of Health, Labour and Welfare Approves AJOVY® (fremanezumab) Injection in Japan for the Preventive Treatment of Migraine in Adults

Retrieved on:

星期三, 六月 23, 2021

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the Ministry of Health, Labour and Welfare (MHLW) has approved the use of AJOVY (fremanezumab) injection for the preventive treatment of migraine in adults in Japan.

Key Points:

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the Ministry of Health, Labour and Welfare (MHLW) has approved the use of AJOVY (fremanezumab) injection for the preventive treatment of migraine in adults in Japan.
Driven by our global mission to improve patients lives, we are pleased to offer this new treatment option to people living with migraine in Japan.
In 2020, the two companies announced outcomes from two pivotal studies of AJOVY in people living with episodic and chronic migraine in Japan.
AJOVY is a calcitonin gene-related peptide antagonist indicated for the preventive treatment of migraine in adults.

Teva to Present Latest Data on AJOVY® (fremanezumab-vfrm) Injection at the 2021 American Headache Society (AHS) Annual Meeting, Showcasing Teva’s Longstanding Heritage in the Management of Migraine

Retrieved on:

星期四, 六月 3, 2021

The data being presented at this years AHS meeting underscore the impact AJOVY can have on the healthcare community as seen in clinical analyses and real-world experiences.

Key Points:

The data being presented at this years AHS meeting underscore the impact AJOVY can have on the healthcare community as seen in clinical analyses and real-world experiences.
AJOVY can be administered in office by a healthcare professional or at home by a patient or caregiver.
AJOVY is a calcitonin gene-related peptide antagonist indicated for the preventive treatment of migraine in adults.
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has been developing and producing medicines to improve peoples lives for more than a century.

Leucadia Pharmaceuticals Launches Calcitonin Salmon Injection

Retrieved on:

星期五, 五月 21, 2021

Peptide hormones, Branches of biology, Calcitonin, Thyroid, Hormones, Endocrine system, Leucadia

b'CARLSBAD, Calif., May 20, 2021 /PRNewswire/ -- Leucadia Pharmaceuticals , a U.S. leader in generic injectables and the commercial arm of Custopharm, Inc. , today announced the launch of its latest FDA-approved generic, Calcitonin Salmon Injection, USP, Synthetic.

Key Points:

b'CARLSBAD, Calif., May 20, 2021 /PRNewswire/ -- Leucadia Pharmaceuticals , a U.S. leader in generic injectables and the commercial arm of Custopharm, Inc. , today announced the launch of its latest FDA-approved generic, Calcitonin Salmon Injection, USP, Synthetic.
"Calcitonin Salmon Injection, USP once again demonstrates Leucadia\'s commitment to the development and launch of critically needed, lower cost therapies in the generic injectables market.
"\nLeucadia Pharmaceuticals\' Calcitonin Salmon Injection, USP, Synthetic FDA approval includes a Competitive Generic Therapy ("CGT") designation.
Leucadia\'s products include Calcitonin Salmon Injection, USP, Synthetic, Acetaminophen Injection, Dihydroergotamine Mesylate Nasal Spray, Icatibant Injection, Sodium Tetradecyl Sulfate (STS) Injection, 3%, Valrubicin Intravesical Solution, USP, Pentobarbital Sodium Injection, USP and Fludarabine Phosphate for Injection, USP.

New Study Published in Cephalalgia Identifies Mechanistic Differences Among CGRP Migraine Treatments

Retrieved on:

星期五, 二月 26, 2021

Health, Clinical trials, General Health, Research, Pharmaceutical, Science, Medical specialties, Branches of biology, Clinical medicine, Monoclonal antibodies, Immunology, Calcitonin gene-related peptide, Neuropeptides, Calcitonin gene-related peptide receptor antagonists, Fremanezumab, Migraine, CALCRL, Calcitonin

This study demonstrated marked differences in the mechanism of blocking the calcitonin gene-related peptide (CGRP) ligand versus the CGRP receptor.

Key Points:

This study demonstrated marked differences in the mechanism of blocking the calcitonin gene-related peptide (CGRP) ligand versus the CGRP receptor.
For instance, fremanezumab in particular, as a monoclonal antibody against the CGRP ligand, is targeted and specific in its mechanism.
AJOVY (fremanezumab-vfrm) injection is a fully humanized IgG2A monoclonal antibody that specifically and solely targets CGRP, a key neuropeptide involved in the pathophysiology of migraine.
Clinical implications of these findings are unknown, but the in vitro studies provide insights into potential mechanistic differences.

Two Spanish companies develop a PCR test that identifies one of the origins of migraine

Retrieved on:

星期三, 九月 16, 2020

Medical specialties, Branches of biology, Hormones, Neurogenic inflammation, Calcitonin gene-related peptide, Neurotransmitters, Peptide hormones, Biogenic amine, Histamine, Calcitonin, Migraine

This test analyzes four variants of the AOC1 gene from a saliva sample (oral mucosa).

Key Points:

This test analyzes four variants of the AOC1 gene from a saliva sample (oral mucosa).
Different mediators have been postulated about the origin of the neurogenic inflammation caused in this pathology, among them the calcitonin gene-related peptide(CGRP) and histamine.
Histamine is a biogenic amine present in multiple physiological functions in the body and also very abundant in our daily diet.
The deficit of this enzyme's activity leads to the accumulation of plasmatic histamine, with a potential risk of suffering from migraine.

Two Spanish companies develop a PCR test that identifies one of the origins of migraine

Retrieved on:

星期三, 九月 16, 2020

Medical specialties, Branches of biology, Hormones, Neurogenic inflammation, Calcitonin gene-related peptide, Neurotransmitters, Peptide hormones, Biogenic amine, Histamine, Calcitonin, Migraine

This test analyzes four variants of the AOC1 gene from a saliva sample (oral mucosa).

Key Points:

This test analyzes four variants of the AOC1 gene from a saliva sample (oral mucosa).
Different mediators have been postulated about the origin of the neurogenic inflammation caused in this pathology, among them the calcitonin gene-related peptide(CGRP) and histamine.
Histamine is a biogenic amine present in multiple physiological functions in the body and also very abundant in our daily diet.
The deficit of this enzyme's activity leads to the accumulation of plasmatic histamine, with a potential risk of suffering from migraine.

Orsini Pharmaceutical Services Selected To Provide VYEPTI™ (eptinezumab-jjmr) - The First And Only Intravenous Preventive Treatment For Migraine

Retrieved on:

星期三, 四月 22, 2020

Migraine, Hormones, Calcitonin gene-related peptide receptor antagonists, Organ systems, Branches of biology, Calcitonin

The approved product is a calcitonin gene-related peptide antagonist indicated for the preventive treatment of migraine in adults.

Key Points:

The approved product is a calcitonin gene-related peptide antagonist indicated for the preventive treatment of migraine in adults.
Migraine is a seriously debilitating condition that afflicts an estimated 39 million people in the U.S., disrupting their lives in significant ways.
The entire team at Orsini looks forward to supporting the needs of migraine sufferers and their caregivers."
The company's comprehensive solutions include nursing coverage nationwide for required in-home infusion services, data analytics, and medication adherence, among others.

2020 Insights into Calcitonin Gene Related Peptide Type 1 Receptor - Featuring Adepthera, Allergan and Amgen Among Others

Retrieved on:

星期三, 三月 25, 2020

Branches of biology, G protein-coupled receptors, Protein families, CALCRL, Calcitonin, Adrenomedullin, RAMP1, RAMP2

According to this report the Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) pipeline Target constitutes close to 6 molecules.

Key Points:

According to this report the Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) pipeline Target constitutes close to 6 molecules.
Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) - Calcitonin receptor-like (CALCRL) also known as the calcitonin receptor-like receptor (CRLR) is a G protein-coupled receptor.
The report 'Calcitonin Gene Related Peptide Type 1 Receptor - Pipeline Review, H1 2020' outlays comprehensive information on the Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.
It also reviews key players involved in Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) targeted therapeutics development with respective active and dormant or discontinued projects.

Catalent Partners with Biohaven on New Fast-Dissolve Migraine Treatment

Retrieved on:

星期二, 三月 17, 2020

Hormones, Dosage forms, Pharmacology, Health, Zydis, Calcitonin gene-related peptide, Calcitonin, Orally disintegrating tablet

NURTEC ODT is the first and only calcitonin gene-related peptide (CGRP) receptor antagonist available in a fast-acting ODT.

Key Points:

NURTEC ODT is the first and only calcitonin gene-related peptide (CGRP) receptor antagonist available in a fast-acting ODT.
Zydis technology is recognized as one of the world's best-performing ODTs and has well-established advantages over conventional oral dosage forms, including improved patient compliance, adherence, and convenience.
NURTEC ODT is the first FDA-approved product for Biohaven, a company dedicated to advancing innovative therapies for neurological diseases.
He added, "We are pleased to have partnered with Biohaven on the formulation, and now commercial manufacture, of this important treatment for such a debilitating condition."

Allergan Receives U.S. FDA Approval for UBRELVY™ for the Acute Treatment of Migraine with or without Aura in Adults

Retrieved on:

星期一, 十二月 23, 2019

Calcitonin gene-related peptide receptor antagonists, Medical specialties, Hormones, Monoclonal antibodies, Branches of biology, Calcitonin gene-related peptide, Neuropeptides, Migraine, Ubrogepant, Calcitonin, Adrenomedullin, CALCRL

UBRELVY is the first and only orally-administered calcitonin gene-related peptide (CGRP) receptor antagonist (gepant) for the treatment of migraine attacks once they start.

Key Points:

UBRELVY is the first and only orally-administered calcitonin gene-related peptide (CGRP) receptor antagonist (gepant) for the treatment of migraine attacks once they start.
In clinical trials supporting the FDA's approval, UBRELVYprovided quick pain relief for the majority of migraine patients.
UBRELVY works in a new way by blocking CGRP, a protein that is released during a migraine attack, from binding to its receptors.
UBRELVYTM(ubrogepant) is indicated for the acute treatment of migraine with or without aura in adults.